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Abstract  41 
BAP1 germline mutations predispose to a cancer predisposition syndrome that includes 42 
mesothelioma, cutaneous melanoma, uveal melanoma and other cancers. This co-occurrence 43 
suggests that these tumors share a common carcinogenic pathway. To evaluate this hypothesis, we 44 
studied 40 Italian families with mesothelioma and/or melanoma. The probands were sequenced for 45 
BAP1and for the most common melanoma predisposition genes (i.e. CDKN2A, CDK4, TERT, MITF 46 
and POT1) to investigate if these genes may also confer susceptibility to mesothelioma. 47 
In two out of six families with both mesothelioma and melanoma we identified either a germline 48 
nonsense mutation (c.1153C>T, p.Arg385*) in BAP1 or a recurrent pathogenic germline mutation 49 
(c.301G>T, p.Gly101Trp) in CDKN2A.  50 
Our study suggests that CDKN2A, in addition to BAP1, could be involved in the melanoma and 51 
mesothelioma susceptibility, leading to the rare familial cancer syndromes. It also suggests that 52 
these tumors share key steps that drive carcinogenesis and that other genes may be involved in 53 
inherited predisposition to malignant mesothelioma and melanoma.  54 
 55 
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1. Introduction  70 
Monogenic cancer predisposition syndromes provide key insights into the complex stepwise 71 
mechanisms of carcinogenesis. Identified in 2011, the inherited cancer predisposition syndrome 72 
caused by germline mutations in the tumor suppressor gene BAP1 (BRCA1-Associated Protein 1) 73 
has shed light for the first time on monogenic malignant mesothelioma (MM) predisposition [1-6]. 74 
However, the BAP1 syndrome spectrum (MIM#614327) includes also other tumors, e.g. cutaneous 75 
melanoma (CM), uveal melanoma (UM) [7-18], epithelioid atypical Spitz tumors [19], lung 76 
adenocarcinoma, meningiomas [20], neuroendocrine tumors, breast cancer, cholangiocarcinoma, 77 
prostate cancer, paraganglioma, renal cell carcinomas [12,21-23] and basal cell carcinoma (BCC) 78 
[24-25]. Recently, our group showed an additional tumor type associated with BAP1 79 
germlinemutation, the rare mucoepidermoid carcinoma [26].  80 
So far 67 families with the BAP1 cancer predisposition syndrome and 56BAP1 germline mutations 81 
have been described [5-6,15-18]. 82 
More information is needed to ascertain the phenotype of this syndrome, including the evolution of 83 
malignant tumors and their response to therapy. Information gained on other cancer-prone 84 
syndromes has shown that peculiar response to treatment should influence treatment choice in 85 
carriers of germline mutations as compared with sporadic tumors (for example, breast and ovarian 86 
cancer due to BRCA1 and BRCA2) [27]. 87 
Thus, to better characterize the BAP1 cancer predisposition syndrome, we identified and studied 40 88 
Italian families with a suspected predisposition for mesothelioma and/or melanoma. BAP1 gene was 89 
sequenced in a representative subject of each family and the same index cases were also studied for 90 
the most common melanoma predisposition genes (i.e. CDKN2A, CDK4, TERT, MITF, POT1) [28-91 
29] to investigate if these genes may also confer susceptibility to mesothelioma. 92 
 93 
2. Materials and Methods 94 
2.1 Probands and Families 95 
We focused only on melanoma and mesothelioma among the BAP1-related tumors because 96 
of our clinical and epidemiological expertise focused on these tumors. 97 
The probands with melanoma were collected from the melanoma databases of the Dermatology 98 
Clinic, AOU Maggiore della Carità (Novara), the Medical Genetics Unit, AOU Città della Salute e 99 
della Scienza (University of Turin), the Medical Genetics Unit, Policlinico S.Orsola-Malpighi 100 
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(University of Bologna), the Clinical Genetics Unit of the Department of Obstetric, Gynecologic 101 
and Pediatric, Arcispedale S. Maria Nuova (Reggio Emilia) and of the Unit of Dermatology 102 
&Plastic Surgery, Campus Biomedico University (Rome).  103 
The probands with mesothelioma were collected from the databases of Mesothelioma Biobank 104 
(Alessandria), Molecular Genetics and Biology Unit, Santa Croce and Carle Hospital (Cuneo), 105 
Thoracic Surgery Unit, AOU Maggiore della Carità (Novara) and Pathology Unit, Sapienza 106 
University (Rome). 107 
Selection criteria for melanoma patients were the following: diagnosis of melanoma with family 108 
history for tumors associated with BAP1 mutations (i.e. uveal melanoma, mesothelioma, renal cell 109 
carcinoma) or juvenile melanoma with family history for melanoma or multiple melanomas with 110 
family history for melanoma. Mesothelioma selection criteria were: familial mesothelioma or 111 
mesothelioma with family history for BAP1 associated tumors or melanoma and mesothelioma in 112 
the same proband or mesothelioma and other tumors occurring in the same subject. 113 
Overall, we identified 40 Italian families classified into three groups (Table I): 6 families with both 114 
mesothelioma and melanoma, 23 families with melanoma (without mesothelioma) and with 115 
familiarity for BAP1 associated tumors and 11 families with mesothelioma (without melanoma) and 116 
with familiarity for BAP1 associated tumors. Details on proband’s tumors with age at diagnosis and 117 
family history are reported in Table I. Pedigrees are shown in Figure 1 (A1,B1,C1) and 118 
Supplementary Figure 1 B1. Histological details, asbestos exposure, Fitzpatrick skin phototype and 119 
other clinical information are described in Supplementary Table I. 120 
All the probands were Caucasian of Italian ancestry and signed an informed consent to participate 121 
in the research project. 122 
 123 
2.2 Histological diagnosis 124 
The diagnosis of melanoma was based on histological and immunochemistry findings. 125 
Histological criteria were related to the evaluation of morphological and cytological features; 126 
antibodies against Human Melanoma Black-45 (HMB-45), S100 protein and p16 were used in 127 
equivocal cases. Melanomas were classified in subtypes, and staged on the basis of the American 128 
Joint Committee on Cancer (AJCC) TNM classification (7th edition) [30].  129 
The diagnosis of mesothelioma was based on standard histological and 130 
immunohistochemical criteria, including positivity to calretinin, vimentin, cytokeratins 5 and 6, and 131 
WT1 and negativity to carcinoembryonic antigen, thyroid transcription factor 1 and Ber-EP4. The 132 
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MMs were classified on the basis of the WHO classification of pleural tumors [31].  133 
 134 
2.3 Information on asbestos exposure of mesothelioma patients 135 
Since asbestos exposure is the main risk factor for MM [32], it was carefully evaluated in all 136 
MM probands. Information on asbestos exposure at work, at home and in the general environment 137 
for index cases included in the Malignant Mesothelioma Registry of the Piedmont Region (RMM) 138 
was collected by RMM using a standardized questionnaire [33], that was administered by trained 139 
interviewers. For familial cases identified in the proband’s pedigree, information was gathered from 140 
their attending clinician’s reports, clinical records and data included in the RMM. Information was 141 
collected during the personal interview of the proband if available. Asbestos exposure was 142 
classified as: high exposure, low exposure, no exposure, unknown exposure. Details are reported in 143 
Betti et al. 2015 [26]. 144 
 145 
2.4 Information on risk factors of melanoma probands 146 
The role of UV exposure is well known in the development of melanoma. People with pale 147 
skin are at higher risk for this tumor. Dysplastic and/or melanocytic nevi are considered 148 
premalignant lesions in melanoma carcinogenesis [34]. Thus, the professional or chronic UV 149 
exposure, the occurrence of dysplastic and/or melanocytic nevi and Fitzpatrick skin phototype were 150 
evaluated in melanoma probands.  151 
 152 
2.5 DNA extraction and Sequencing analyses 153 
Blood samples were collected in vacutainers with ethylenediaminetetraacetic acid (EDTA) 154 
and stored at -20°C until use. Genomic DNA was extracted from peripheral blood using QIAamp® 155 
DNA Blood Maxi Kit (QIAGEN, Valencia, CA, USA), according to the manufacturer’s protocol.  156 
The 17 exons, intron-exon boundaries and promoter region (~1000bp upstream of the ATG) 157 
ofBAP1 (NM_004656.2), the exons and intron-exon boundaries of CDKN2A (NM_000077.4), the 158 
exon 2 of CDK4 (NM_000075.3), the promoter of TERT (NM_198253.2), the missense variant 159 
p.Glu318Lys of MITF (NM_000248.3) and the exon 10 of POT1 (NM_015450) were amplified. 160 
The primers were designed using the reference sequences provided by NCBI or Ensembl databases 161 
(Supplementary Table II).  162 
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PCR reactions were performed in a 25 µL volume using GoTaq® Flexi Polymerase 163 
(PROMEGA, Madison, WI, USA) for BAP1 fragments amplification and Taq Gold 360+GC 164 
enhancer for fragments amplification of melanoma predisposition genes. Sanger sequencing was 165 
done using ABI PRISM 3130xl Genetic Analyzer or by IGA Technology Services (Udine, Italy). 166 
Sequences were read by aligning with the reference sequence, using the GENESTREAM II Align 167 
tool.  168 
Each variant was confirmed on DNA obtained from a second independent blood vial.  169 
Segregation analysis of three variants was done on DNA extracted from blood samples or tumor 170 
FFPE of key relatives. 171 
 172 
 2.6 Loss-of-heterozygosity analysis 173 
 To assess loss-of-heterozygosity (LOH), we performed Sanger sequencing and microsatellite 174 
analysis on DNA obtained from tumor portions of FFPE (Formalin-fixed paraffin-embedded) 175 
biopsy specimens. For each sample three serial 10µm thick sections were cut using microtome. The 176 
slides were heated at 60°C for 30 min. The paraffin-embedded tissues were processed with xylene 177 
and absolute ethanol. Deparaffinized tissues were scraped from the slides and placed in 1.5 ml-178 
Eppendorf tubes. DNA was purified using QIAamp® DNA FFPE Tissue Kit (QIAGEN, Valencia, 179 
CA, USA) according to the manufacturer’s protocol. 180 
Sanger sequencing of the mutated region was then performed.LOH was indicated by loss of the 181 
wild type allele in the mutation site. 182 
Microsatellite analysis was performed using three markers (D3S3026, D3S3561 and D3S1578) 183 
flanking the BAP1 gene [20]. The analysis was carried out on genomic and tumor DNAs. Amplified 184 
PCR products were separated with ABI 3130xl Genetic Analyzer and fragments were analyzed 185 
using GeneMapper. LOH was indicated by apparent homozygosity at the microsatellite sites. 186 
 187 
2.7 Immunohistochemistry analysis 188 
To ascertain the role of germline BAP1 or CDKN2A mutations, protein expression was evaluated 189 
by immunohistochemistry (IHC) using a standard automated immunostainer (BenchMark, 190 
Ventana Medical System, Tucson AZ). 191 
Specific primary antibody against the anti-human BAP1 (mouse monoclonal, clone C-4, Santa 192 
Cruz Biotechnology, Inc., Santa Cruz, CA) and anti-p16INK4a (mouse monoclonal, CLONE E6H4, 193 
Ventana Medical System, Tucson, AZ) were used, respectively. 194 
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BAP1 was considered positive when a weak-to-strong nuclear positivity was shown. The specificity 195 
of BAP1 stain was validated in serial negative control sections by omitting the primary antibody for 196 
each immunohistochemical run. Non-neoplastic cells, such as vascular endothelium or 197 
inflammatory cells, were considered as internal positive controls. 198 
To detect the p16 protein, every tumor was given a score according to the intensity of the nuclear or 199 
cytoplasmic staining (no staining; weak staining; moderate staining; strong staining). A stained 200 
slide with a high-degree intraepithelial lesion of the uterine cervix was used as a positive control.  201 
 202 
2.8 In silico prediction analyses 203 
Pathogenicity assessment of missense variants is an important problem in cancer 204 
predisposition syndrome [35]. 205 
To address the problem concerning BAP1 missense variants, we have considered the following 206 
parameters: results of LOH assay, results of IHC, frequency in 1000 Genomes Project and ExAC 207 
databases, disease-causing potential using seven different prediction tools (Mutation taster, SIFT, 208 
Provean, Polyphen-2, Mutation assessor, Condel, Phyre2), segregation analysis. 209 
Since a change in a coding sequence may activate a cryptic splice site, we have also evaluated 210 
splice site prediction using seven different tools (Human Splicing Finder, MaxEnt, BDGP, 211 
NetGene2, GeneScan, FGENESH 2.6, FSPLICE 1.0). 212 
As controls for the prediction programs, we used the five most frequent missense variants in ExAC, 213 
(these variants are expected to be silent changes, since they are commonly found in normal 214 
individuals). 215 
We considered LOH, IHC or splice site prediction as the most important parameters. If LOH and 216 
IHC data were not available, we considered as pathogenic a missense variant that has a disease 217 
causing potential for at least 5/7 tools.  218 
Segregation should be evaluated taking into consideration that frequent cancers may also occur as 219 
phenocopies, i.e. patient with cancer but without the mutation identified in other affected family 220 
members. Phenocopies are events not so rare in inherited cancer predisposition syndromes. 221 
 222 
2.9 Multiplex Ligation-dependent Probe Amplification (MLPA)  223 
MLPA was used to evaluate the presence of copy number variations. MLPA assays were 224 
performed on 100-200ng of genomic DNAs using the SALSA MLPA P417 BAP1 probemix and 225 
the SALSA MLPA probemix P419-A1 CDKN2A/2B-CDK4 Melanoma according to instructions 226 
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provided by the manufacturer (MRC-Holland, Amsterdam, The Netherlands). Amplified PCR 227 
products were separated with ABI 3130xl Genetic Analyzer and fragments were analyzed using 228 
Coffalyser.NET software (MRC-Holland). 229 
 230 
3. Results 231 
3.1 Risk factors 232 
Information on asbestos exposure was available for 10 out of 12 mesothelioma probands 233 
(Supplementary Table I). All of them showed asbestos exposure, in agreement with literature [32]. 234 
Possible occupational exposure was reported for four probands, para-occupational or household 235 
exposure forfive patients and both possible occupational and household exposure for one proband. 236 
One out of 28 melanoma probands showed professional or chronic UV exposure. 237 
Information regarding Fitzpatrick skin phototype was available for 16 out of 28 probands: one had 238 
phototype I, 10 had phototype II and 5 had phototype III. Information about dysplastic and/or 239 
melanocytic nevi was available for 13 patients. Whereas one proband showed dysplastic nevi, 13 240 
showed melanocytic nevi (7 probands <10, 2 probands 10-50, 4 probands >50). In total, 17 out of 241 
28 probands showed at least well-documented risk factor (Supplementary Table I). Even if 242 
information is lacking for 11 probands, our data confirms the high occurrence of well-documented 243 
risk factors in melanoma patients [34]. 244 
 245 
3.2 Mutation analysis 246 
Among the 40 probands with a family history of cancer we identified four BAP1 germline 247 
variants and a recurrent pathogenic germline mutation in CDKN2A in three and one index cases, 248 
respectively (Table I).  249 
Two BAP1 and one CDKN2A germline variants were found in families with both 250 
mesothelioma and melanoma. Two other BAP1 germline variants were identified in a patient with 251 
multiple cutaneous amelanotic melanomas (Table I). 252 
The proband of family ID5 carried a heterozygous nonsense mutation in BAP1 gene 253 
(c.1153C>T, p.Arg385*, exon 12) (II-4 PB, Figure 1 A2). The mutation seemed heterozygous also 254 
in the tumor samples (II-4 CM, II-4 MM, Figure 1 A2) and microsatellite analysis did not reveal 255 
evidence of LOH (data not shown). However, IHC did not reveal any BAP1 nuclear expression in 256 
both melanoma and mesothelioma cells (II-4 CM, II-4 MM, Figure 1A3). It is thus possible that the 257 
second inactivating “hit” was either a somatic point mutation or a methylation event. This mutation 258 
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has been previously reported in three families with Spitz tumors and ocular and cutaneous 259 
melanoma [8,14], but this is the first report in association with MM. The proband developed two 260 
independent cutaneous melanomas (53, 57yrs), a meningioma (37yrs) and an epithelioid pleural 261 
mesothelioma (53yrs) (Figure 1 A1, Table I). The mutation was transmitted to the proband’s 262 
healthy daughter (III-2 PB, Figure 1 A2) while the proband’s brother died because of a basal cell 263 
carcinoma, but no sample was available for segregation analysis. 264 
The proband of melanoma family ID16 developed two cutaneous amelanotic melanomas and 265 
showed a BAP1 missense variant (c.1700A>C, p.Asp567Ala, exon 13) (IV-1 PB, Figure 1 B2) and 266 
a 5bp duplication in the promoter region (c.-594dupCCCGT) (IV-1 PB, Supplementary Figure 1 267 
A1). Sequencing analysis of both parents confirmed that these variants were inherited in cis from 268 
the mother (III-5 PB, Figure 1 B2 and Supplementary Figure 1 A1), who presented with a non-269 
Hodgkin cutaneous lymphoma. A healthy maternal aunt and a proband’s healthy sister were also 270 
carriers (III-6 PB, IV-2 PB respectively, Figure 1 B2 and Supplementary Figure 1 A1). On the other 271 
hand, the proband’s healthy father and the paternal uncle affected by cutaneous melanoma did not 272 
carry the variant allele. Thus, the cutaneous pigmented melanoma presented by the proband’s 273 
paternal uncle was not due to the aforementioned BAP1 germline variants. 274 
The missense variant appeared in heterozygous state also in the two melanomas from the proband 275 
(IV-1 CM_1, IV-1 CM_2, Figure 1 B2).  276 
Microsatellites analysis, performed on genomic and tumor DNAs, showed a decreased amount of 277 
the shorter paternal allele for the only informative marker (D3S3026) (IV-1 CM_1, IV-1 CM_2, 278 
Figure 1 B3).Considering a stromal cell contamination of tumor DNA from melanoma samples 279 
(determined as 64% in average, 15-90%) [36], this result suggests the loss of the wild type allele 280 
(LOH). 281 
The presence of BAP1 protein was ascertained by IHC on FFPE pertaining to the two different 282 
melanomas from the proband (IV-1 CM_1, IV-1 CM_2, Figure 1 B4). BAP1 was normally 283 
expressed in the nucleus, showing that both the promoter duplication and the missense variant do 284 
not drastically affect protein levels. Since IHC is not quantitative, this result does not conflict with a 285 
tumor genotype that includes an expressed allele with a missense variant and a somatic deletion that 286 
abolishes the expression of the wild type protein. 287 
To assess the pathogenicity of this missense variant, we have comparedthe p.Asp567Ala 288 
with all the eleven BAP1 missense variants reported so far in patients with familiarity for BAP1 289 
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associated tumors (Supplementary Table III) using the parameters reported in the Materials and 290 
Methods section. 291 
Using these parameters, 7/12 variants could be considered as disease causing. Two of them are 292 
predicted to cause aberrant splicing. One of these was experimentally confirmed [21], the second 293 
was not tested by the authors [6]. The other missense variants should be considered as variant of 294 
unknown significance (VUS), including p.Asp567Ala. 295 
We have also performed a prediction of the three dimensional structure of the variant protein 296 
according to Protein Homology/analogy Recognition Engine v.2 (Phyre2). The mutant hydrophobic 297 
Ala567 is predicted to be buried within the globular portion of the protein and the relevant domains 298 
of the BAP1 protein seem to assume a different position (Supplementary Figure 2).  299 
In conclusion, a functional assay is strongly needed to assess the pathogenicity of missense variants 300 
including p.Asp567Ala. 301 
The duplication in the promoter was predicted to remove a MAZ (MYC-Associated Zinc Finger 302 
Protein) binding site by PROMO (TRANSFAC), but has no effect on transcription factor binding 303 
by AliBaba 2.1. The duplication is not reported in public databases (NCBI dbSNPs, 1000 Genomes 304 
Project phase 3, Exome Variant Server, Exome Aggregation Consortium at march 2015). Thus, 305 
considering that the protein is expressed, our data overall suggest that the duplication is a likely 306 
neutral variant. 307 
The proband of family ID4 showed a heterozygote 19bp duplication (c.-308 
247dupCCTTCGCCCCCGTCCCTCC) in the BAP1 promoter region (II-1 PB, Supplementary 309 
Figure 1 B2) not reported in the above mentioned databases. This variant is predicted to generate an 310 
ETF binding site by AliBaba 2.1, but has no effect on transcription factor binding site by PROMO 311 
(TRANSFAC). IHC performed on the mesothelioma tissue showed nuclear expression of BAP1 312 
protein (data not shown), supporting the hypothesis that this variant does not significantly alter gene 313 
transcription and could be considered as VUS. This family included both melanoma and MM in its 314 
tumor spectrum, but additional specimens were not available for further studies. 315 
Probands from the other families were analyzed using the same strategy, but no other 316 
germline variant was found in BAP1 gene.  317 
Conversely, a recurrent pathogenic germline mutation (c.301G>T, p.Gly101Trp, exon 2) in 318 
CDKN2A was found in the family ID3 showing both melanoma and mesothelioma. The CDKN2A 319 
germline mutation was carried by the proband affected by cutaneous melanoma and by her mother 320 
affected by both cutaneous melanoma and mesothelioma (III-3 PB, II-3 FFPE non-tumor tissue 321 
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respectively, Figure 1 C2). This mutation was found in heterozygosity with the wild type sequence 322 
also in mesothelioma from the proband’s mother (II-3 MM, Figure 1 C2).  323 
Mesothelioma cells showed nuclear staining at IHC with anti-p16 antibody (II-3 MM, Figure 1 C3) 324 
although the intensity of nuclear expression was slightly lower in less differentiated tumor cells. 325 
MLPA analysis was performed on germline DNA from all the probands, but no copy 326 
number variations has been identified.  327 
The probands from the other families under study were sequenced for the most common 328 
melanoma predisposition genes (CDKN2A, CDK4 exon 2, TERT promoter, MITF exon 9, POT1 329 
exon 10), but no additional germline variant was found. Details of the results for each proband are 330 
reported in Table 1. 331 
 332 
4. Discussion 333 
Malignant mesothelioma is a rare and aggressive tumor that mainly arise from the pleura 334 
and the peritoneum. The main risk factor is asbestos exposure [32]. Over 80% of MM patients have 335 
a history of asbestos exposure, but only 10-17% of individuals heavily exposed to asbestos develop 336 
MM [37]. Moreover, several families with multiples cases of MM have been described [38-41]. 337 
These observations suggest the involvement of inherited factors in the pathogenesis of MM. A 338 
single high penetrance MM predisposition gene, BAP1, has been so far reported in familial cases of 339 
MM [1]. Previous observations from our group and other researchers [26,42-43] limit the role of the 340 
BAP1 predisposition to the familial cases, as the mutation detection rate among sporadic cases 341 
showing the mutations is less than 2% [26]. 342 
Cutaneous melanoma (CM) and uveal melanoma (UM) are also aggressive tumors that 343 
originate from melanocytes of the skin and the eye, respectively. CM is responsible for 75% of 344 
deaths from skin cancer [34] whereas UM accounts for less than 4% of all melanoma cases [44]. 345 
Although UV radiations are awell known environmental risk factor, 10% of melanomas are familial 346 
regardless sun exposure or skin phototype. A subset of families (50%) carries mutations in one of 347 
the known high penetrance melanoma predisposition genes: CDKN2A, CDK4, POT1, TERT, MITF 348 
and BAP1 [45].  349 
Thus, germline mutations in BAP1 are thought to be responsible for both MM and familial 350 
melanoma. Within the 67 families identified so far as affected by this syndrome, 18 showed both 351 
melanoma and mesothelioma [5-6,15-18]. Interestingly, six families from our series included 352 
patients with mesothelioma and melanoma. 353 
12 
 
To better characterize the BAP1 cancer syndrome we sequenced BAP1 in 40 Italian families 354 
in which multiple cases of either MM or melanoma, or cases of both malignancies occurred. 355 
Moreover, we reasoned that given the shared predisposition for these tumors due to BAP1, other 356 
genes predisposing to melanoma could also predispose to MM. Thus, we also analysed CDKN2A, 357 
CDK4, TERT, MITF and POT1 in the MM families. 358 
We identified a germline BAP1 truncating mutation (c.1153C>T, p.Arg385*) in a patient 359 
who developed both MM and melanoma (Family ID5). This nonsense mutation has been previously 360 
identified in three families with familial melanoma [8,14], but never in MM. This patient is still 361 
alive five years after the diagnosis of epithelioid MM and was not heavily exposed to asbestos. 362 
Epithelioid histology, long survival and low asbestos exposure have all been described in patients 363 
with MM carrying germline BAP1 mutations [1,46-48]. Further studies are needed to ascertain 364 
whether these aspects are typical of the BAP1 cancer syndrome. However, it is possible that studies 365 
on familial predispositions are biased towards an over representation of long-survivors while short 366 
survival might hamper sample collection and proper investigation.  367 
A further patient (Family ID4), whose father died of MM, developed cutaneous melanoma 368 
and breast cancer and carried a germline 19bp duplication in BAP1 promoter region (c.-247dup 369 
CCTTCGCCCCCGTCCCTCC). This VUS is not included in public databases, but could not be 370 
traced in segregation analysis because key relatives were not available. 371 
Our study also stresses the need of a reliable functional assay to evaluate the pathogenicity 372 
of missense variants. In fact, the use of multiple in silico prediction tools did not allow to assess the 373 
pathogenicity of the p.Asp567Ala variant found in a patient with multiple melanomas (family 374 
ID16). 375 
Finally, looking for mutations in the familial melanoma genes we found a germline 376 
CDKN2A mutation in family ID3 (c.301G>T, p.Gly101Trp). This mutation has been frequently 377 
identified in familial melanoma (44%) [49]. The proband was diagnosed with cutaneous melanoma, 378 
whereas her mother had both cutaneous melanoma and MM. Mesothelioma tissue of the proband’s 379 
mother showed p16 nuclear expression. A retained p16 expression for this mutation is reported in 380 
literature for melanoma [50]. Ghiorzo et al., reported that 28 out of 30 Gly101Trp-positive 381 
melanoma samples retained p16 expression and in 25 of these, p16 expression was predominantly 382 
nuclear. 383 
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Asbestos exposure at work of the proband's mother was assessed as 'low exposure', a 384 
category including all occupational exposures occurring outside industries were asbestos was 385 
directly used as a raw material.  386 
Patients with BAP1 mutations seem to develop mesothelioma even after a low asbestos 387 
exposure [1]. Our finding suggests that the CDKN2A p.Gly101Trp behaves as BAP1 mutations: the 388 
mutation carrier is at high risk for tumors and the type of carcinogen exposure is important for the 389 
cancer type that is developed. In conclusion, our study suggests for the first time that also CDKN2A 390 
may predispose to MM.  391 
Although the coincidence of two rare tumors in a single patient promptly suggests a 392 
common origin, we cannot exclude the independent occurrence of a malignant mesothelioma in a 393 
patient otherwise predisposed to melanoma. Indeed, we failed to identify additional CDKN2A 394 
germline mutations in our series but the same is true for BAP1 whose mutations are very rare and do 395 
not explain most familial clustering of tumors investigated in this work, as well as cases or families 396 
with both melanoma and renal cell cancer.  397 
Both BAP1 and CDKN2A genes are found somatically deleted or mutated in MM tissues 398 
[51]. This study further supports that loss of either BAP1 or CDKN2A is an important step in both 399 
melanoma and MM carcinogenesis and individuals that carry a germline mutation in either of these 400 
two genes might have an increased risk for both tumors. 401 
Three other families (IDs 1,2,6) showed co-occurrence of MM and melanoma. The fact that 402 
none of these families showed germline mutations in either BAP1 or CDKN2A, CDK4, TERT, MITF 403 
and POT1 suggests that other genes may be involved in melanoma and MM shared predisposition. 404 
Other cancer predisposition syndromes have been reportedly associated with both tumors. Patients 405 
with Li Fraumeni syndrome due to TP53mutations frequently develop melanoma [52-53], more 406 
rarely MM [54]. Moreover, the occurrence of both melanoma and mesothelioma has been reported 407 
in a patient with neurofibromatosis type 2, due to heterozygous germline mutations in NF2 [55-57]. 408 
Both TP53 and NF2 are often somatically deleted in MM. Thus, at least four genes that cause 409 
inherited cancer predisposition syndromes, including MM and melanoma in their spectrum, are 410 
often subjected to inactivating somatic mutations or deletions both in melanoma and MM [7,58-59]. 411 
An occurrence of MM as a second tumor after melanoma was reported two-fold more frequently 412 
than expected (p<0.05, in males) in a recent survey performed on Italian cancer registries [60]. A 413 
genetic susceptibility may explain the statistically significant co-occurrence of the two tumors in the 414 
same individual. 415 
14 
 
A common denominator between mesothelioma and melanoma is also the well-defined role of 416 
environmental carcinogens. In mice, germline Bap1 mutations increase the susceptibility to 417 
asbestos-induced mesothelioma formation [61] and BAP1 mutation carriers may be prone to UV 418 
carcinogenesis and melanoma development [5]. 419 
Our study suggests that CDKN2A, in addition to BAP1, could be involved in melanoma and 420 
mesothelioma susceptibility and these tumors share key steps that drive carcinogenesis and may 421 
cause familial aggregations of cases. Our hypothesis should be confirmed on a larger patients serie. 422 
Our study also suggests that other unknown genes may be involved in familial MM or familial 423 
melanoma, including uveal melanoma. Exome-sequencing analysis in families that show both MM 424 
and melanoma could help to identify new genes involved in the shared susceptibility between these 425 
tumors.  426 
 427 
Acknowledegments 428 
We wish to thank all of the patients who generously participated to this study, Dr. Guido Casalis 429 
Cavalchini for contributing cases to this series, Prof. Emanuele Albano for helpful discussion, and 430 
Ms.Victoria Franzinetti for the careful revision of the text. 431 
This study was supported by Istituto Superiore di Sanità (Progetto Amianto) (to C. Magnani in 432 
collaboration with I. Dianzani), HuGeF, Compagnia di San Paolo and AIRC (IG 174646) (to G. 433 
Matullo).  434 
 435 
References  436 
[1] Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, 437 
Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M, Gaudino G, Yang H, Carbone M. 2011. Germline BAP1 438 
mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022-5. doi: 10.1038/ng.912. 439 
[2] Wiesner T, Fried I, Ulz P, Stacher E, Popper H, Murali R, Kutzner H, Lax S, Smolle-Juttner F, Geigl JB, Speicher 440 
MR. 2012. Toward an improved definition of the tumor spectrum associated with BAP1 germline mutations. J Clin 441 
Oncol 30(32):e337-40. doi: 10.1200/JCO.2011.41.2965. 442 
[3] Ribeiro C, Campelos S, Moura CS, Machado JC, Justino A, Parente B. 2013. Well-differentiated papillary 443 
mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation. Ann Oncol 24:2147-50. doi: 444 
10.1093/annonc/mdt135. 445 
[4] Cheung M, Talarchek J, Schindeler K, Saraiva E, Penney LS, Ludman M, Testa JR. 2013.Further evidence for 446 
germline BAP1 mutations predisposing to melanoma and malignant mesothelioma. Cancer Genet 206:206-10. doi: 447 
10.1016/j.cancergen.2013.05.018. 448 
[5] Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar JA, Kayaleh OR, Testa JR. 2015. Germline BAP1 mutation in a 449 
family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer 450 
Lett369(2):261-5. doi: 10.1016/j.canlet.2015.09.011. 451 
[6] Ohar JA, Cheung M, Talarchek J, Howard SE, Howard TD, Hesdorffer M, Peng H, Rauscher FJ, Testa JR. 2016. 452 
Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant Mesothelioma Patients with Family History of 453 
Cancer. Cancer Res 76(2):206-15. doi: 10.1158/0008-5472.CAN-15-0295. 454 
[7] Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, Windpassinger C, Wackernagel W, Loy S, Wolf I, 455 
Viale A, Lash AE, Pirun M, Socci ND, Rütten A, Palmedo G, Abramson D, Offit K, Ott A, Becker JC, Cerroni L, 456 
Kutzner H, Bastian BC, Speicher MR. 2011. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 457 
43(10):1018-21. doi: 10.1038/ng.910. 458 
[8] Njauw CN, Kim I, Piris A, Gabree M, Taylor M, Lane AM, DeAngelis MM, Gragoudas E, Duncan LM, Tsao H. 459 
2012.Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular 460 
melanoma families. PLoS One 7:e35295.doi: 10.1371/journal.pone.0035295. 461 
[9] Aoude LG, Wadt K, Bojesen A, Crüger D, Borg A, Trent JM, Brown KM, Gerdes AM, Jönsson G, Hayward NK. 462 
15 
 
2013. A BAP1 Mutation in a Danish Family Predisposes to Uveal Melanoma and Other Cancers. PloS One 8:e72144. 463 
doi: 10.1371/journal.pone.0072144. 464 
[10] Hoiom V, Edsgard D, Helgadottir H, Eriksson H, All-Ericsson C, Tuominen R, Ivanova I, Lundeberg J, 465 
Emanuelsson O, Hansson J. 2013. Hereditary uveal melanoma: A report of a germline mutation in BAP1. Genes 466 
Chromosomes Cancer 52(4):378-84. doi: 10.1002/gcc.22035. 467 
[11] Maerker DA, Zeschnigk M, Nelles J, Lohmann DR, Worm K, Bosserhoff AK, Krupar R, Jägle H. 2014. BAP1 468 
germline mutation in two first grade family members with uveal melanoma. Br J Ophthalmol 98:224-227. doi: 469 
10.1136/bjophthalmol-2013-303814. 470 
[12] Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong L, McGillivray B, Asrat MJ, Davidorf FH, Abdel-471 
Rahman MH. 2014. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome, reporting 472 
three new cases. Genes Chromosomes Cancer 53(2):177-82. doi: 10.1002/gcc.22129. 473 
[13] Cebulla CM, Binkley EM, Pilarski R, Massengill JB, Rai K, Liebner DA, Marino MJ, Singh AD, Abdel-Rahman 474 
MH. 2015. Analysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients. Ophthalmic Genet 475 
36(2):126-31. doi: 10.3109/13816810.2015.1010734. 476 
[14] Gupta MP, Lane AM, DeAngelis MM, Mayne K, Crabtree M, Gragoudas ES, Kim IK. 2015. Clinical 477 
Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations. JAMA Ophthalmol 133(8):881-7. doi: 478 
10.1001/jamaophthalmol.2015.1119. 479 
[15] Gerami P, Yélamos O, Lee CY, Obregon R, Yazdan P, Sholl LM, Guitart GE, Njauw CN, Tsao H. 2015. Multiple 480 
Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation. JAMA 481 
Dermatol 151(11):1235-9. doi: 10.1001/jamadermatol.2015.1701. 482 
[16] Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH. 2016. Comprehensive review of BAP1 tumor predisposition 483 
syndrome with report of two new cases.Clin Genet 89(3):285-94. doi: 10.1111/cge.12630. 484 
[17] Klebe S, Driml J, Nasu M, Pastorino S, Zangiabadi A, Henderson D, Carbone M. 2015. BAP1 hereditary cancer 485 
predisposition syndrome: a case report and review of literature. Biomark Res 3:14.doi: 10.1186/s40364-015-0040-5. 486 
[18] McDonnell KJ, Gallanis GT, Heller KA, Melas M, Idos GE, Culver JO, Martin SE, Peng DH, Gruber SB. 2016. A 487 
novel BAP1 mutation is associated with melanocytic neoplasms and thyroid cancer. Cancer Genet 209(3):75-81.doi: 488 
10.1016/j.cancergen.2015.12.007. 489 
[19] Busam KJ, Wanna M, Wiesner T. Multiple epithelioid Spitz nevi or tumors with loss of BAP1 expression: a clue to 490 
a hereditary tumor syndrome. JAMA Dermatol. 2013 Mar;149(3):335-9. doi: 10.1001/jamadermatol.2013.1529. 491 
[20] Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH. 492 
2011. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. 493 
J Med Genet 48(12):856-9. doi: 10.1136/jmedgenet-2011-100156. 494 
[21] Wadt K, Choi J, Chung JY, Kiilgaard J, Heegaard S, Drzewiecki KT, Trent JM, Hewitt SM, Hayward NK, Gerdes 495 
AM, Brown KM. 2012. A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and 496 
paraganglioma. Pigment Cell Melanoma Res 25(6):815-8.  497 
[22] Popova T, Hebert L, Jacquemin V, Gad S, Caux-Moncoutier V, Dubois-d'Enghien C, Richaudeau B, Renaudin X, 498 
Sellers J, Nicolas A, Sastre-Garau X, Desjardins L, Gyapay G, Raynal V, Sinilnikova OM, Andrieu N, Manié E, de 499 
Pauw A, Gesta P, Bonadona V, Maugard CM, Penet C, Avril MF, Barillot E, Cabaret O, Delattre O, Richard S, Caron 500 
O, Benfodda M, Hu HH, Soufir N, Bressac-de Paillerets B, Stoppa-Lyonnet D, Stern MH. 2013. Germline BAP1 501 
Mutations Predispose to Renal Cell Carcinomas. Am J Hum Genet 92:974-980. doi: 10.1016/j.ajhg.2013.04.012. 502 
[23] Farley MN, Schmidt LS, Mester JL, Peña-Llopis S, Pavia-Jimenez A, Christie A, Vocke CD, Ricketts CJ, Peterson 503 
J, Middelton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie XJ, Dahia PL, Eng C, Linehan WM, 504 
Brugarolas J. 2013. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol 505 
Cancer Res 11(9):1061-71. doi: 10.1158/1541-7786.MCR-13-0111. 506 
[24] Wadt KA, Aoude LG, Johansson P, Solinas A, Pritchard A, Crainic O, Andersen MT, Kiilgaard JF, Heegaard S, 507 
Sunde L, Federspiel B, Madore J, Thompson JF, McCarthy SW, Goodwin A, Tsao H, Jönsson G, Busam K, Gupta R, 508 
Trent JM, Gerdes AM, Brown KM, Scolyer RA, Hayward NK. 2015. A recurrent germline BAP1 mutation and 509 
extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma. Clin Genet 88(3):267-72. doi: 510 
10.1111/cge.12501. 511 
[25] de la Fouchardière A, Cabaret O, Savin L, Combemale P, Schvartz H, Penet C, Bonadona V, Soufir N, Bressac-de 512 
Paillerets B. 2015. Germline BAP1 mutations predispose also to multiple basal cell carcinomas. Clin Genet 88(3):273-513 
7.  doi: 10.1111/cge.12472. 514 
[26] Betti M, Casalone E, Ferrante D, Romanelli A, Grosso F, Guarrera S, Righi L, Vatrano S, Pelosi G, Libener R, 515 
Mirabelli D, Boldorini R, Casadio C, Papotti M, Matullo G, Magnani C, Dianzani I. 2015. Inference on germline BAP1 516 
mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area. Genes 517 
Chromosomes Cancer 54(1):51-62. doi: 10.1002/gcc.22218. 518 
16 
 
[27] Moreno L, Linossi C, Esteban I, Gadea N, Carrasco E, Bonache S, Gutiérrez-Enríquez S, Cruz C, Díez O, Balmaña 519 
J. Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer 520 
therapeutics. Clin Transl Oncol. 2016 Jan 7. 521 
[28] Hill VK, Gartner JJ, Samuels Y, Goldstein AM. 2013. The genetics of melanoma: recent advances. Annu Rev 522 
Genomics Hum Genet 14:257-79. doi: 10.1146/annurev-genom-091212-153429. 523 
[29] Shi J, Yang XR, Ballew B, Rotunno M, Calista D, Fargnoli MC, Ghiorzo P, Bressac-de Paillerets B, Nagore E, 524 
Avril MF, Caporaso NE, McMaster ML, Cullen M, Wang Z, Zhang X; NCI DCEG Cancer Sequencing Working 525 
Group; NCI DCEG Cancer Genomics Research Laboratory; French Familial Melanoma Study Group, Bruno W5, 526 
Pastorino L, Queirolo P, Banuls-Roca J, Garcia-Casado Z, Vaysse A, Mohamdi H, Riazalhosseini Y, Foglio M, Jouenne 527 
F, Hua X, Hyland PL, Yin J, Vallabhaneni H, Chai W, Minghetti P, Pellegrini C, Ravichandran S, Eggermont A, 528 
Lathrop M, Peris K, Scarra GB, Landi G, Savage SA, Sampson JN, He J, Yeager M, Goldin LR, Demenais F, Chanock 529 
SJ, Tucker MA, Goldstein AM, Liu Y, Landi MT. 2014. Rare missense variants in POT1 predispose to familial 530 
cutaneous malignant melanoma. Nat Genet 46(5):482-6. doi: 10.1038/ng.2941. 531 
[30] Edge SB, Compton CC. 2010. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer 532 
staging manual and the future of TNM. Ann SurgOncol 17(6):1471-4. doi: 10.1245/s10434-010-0985-4. 533 
[31] Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. 2015. Introduction to The 2015 World Health 534 
Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart.JThoracOncol 10(9):1240-2. doi: 535 
10.1097/JTO.0000000000000663. 536 
[32] Pinto C, Novello S, Torri V, Ardizzoni A, Betta PG, Bertazzi PA, Casalini GA, Fava C, Fubini B, Magnani C, 537 
Mirabelli D, Papotti M, Ricardi U, Rocco G, Pastorino U, Tassi G, Trodella L, Zompatori M, Scagliotti G. 2013. 538 
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations.Cancer 539 
Treat Rev39(4):328-39. doi: 10.1016/j.ctrv.2012.11.004.  540 
[33] Magnani C, Agudo A, González CA, Andrion A, Calleja A, Chellini E, Dalmasso P, Escolar A, Hernandez S, 541 
Ivaldi C, Mirabelli D, Ramirez J, Turuguet D, Usel M, Terracini B. 2000. Multicentric study on malignant pleural 542 
mesothelioma and non-occupational exposure to asbestos.British Journal of Cancer.83, 104–11. 543 
[34] Potrony M, Badenas C, Aguilera P, Puig-Butille JA, Carrera C, Malvehy J, Puig S. 2015. Update in genetic 544 
susceptibility in melanoma. Ann Transl Med 3(15):210. Review. doi: 10.3978/j.issn.2305-5839.2015.08.11. 545 
[35] Medeiros F, Lindor NM, Couch FJ, Highsmith WE Jr. The germline MLH1 K618A variant and susceptibility to 546 
Lynch syndrome-associated tumors.J MolDiagn. 2012 May-Jun; 14(3):264-73. doi:10.1016/j.jmoldx.2012.01.006. 547 
[36] Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, 548 
Rickaby W, D'Arrigo C, Robson A, Bastian BC. 2015. The Genetic Evolution of Melanoma from Precursor Lesions. N 549 
Engl J Med 373(20):1926-36. doi: 10.1056/NEJMoa1502583. 550 
[37] Hodgson JT, Darnton A. 2000. The Quantitative Risks of Mesothelioma and Lung Cancer in Relation to Asbestos 551 
Exposure.AnnOccupHyg 44:565–601.doi: 10.1136/oem.2009.052860. 552 
[38] Ascoli V, Cavone D, Merler E, Barbieri PG, Romeo L, Nardi F, Musti M. 2007. Mesothelioma in blood related 553 
subjects: report of 11 clusters among 1954 Italy cases and review of the literature. Am J IndMed 50(5):357-69. 554 
[39] Ascoli V, Romeo E, Carnovale Scalzo C, Cozzi I, Ancona L, Caraviani F, Balestri A, Gasperini L, Forastiere F. 555 
2014. Familial malignant mesothelioma: a population-based study in Central Italy (1980-2012). Cancer Epidemiol 556 
38:273-278.doi: 10.1016/j.canep.2014.02.014. 557 
[40] Dogan AU, Baris YI, Dogan M, Emri S, Steele I, Elmishad AG, Carbone M. 2006. Genetic predisposition to fiber 558 
carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 66(10):5063-8.  559 
[41] de Klerk N, Alfonso H, Olsen N, Reid A, Sleith J, Palmer L, Berry G, Musk AB. 2013. Familial aggregation of 560 
malignant mesothelioma in former workers and residents of Wittenoom, Western Australia. Int J Cancer132(6):1423-8. 561 
doi: 10.1002/ijc.27758. 562 
[42] Rusch A, Ziltener G, Nackaerts K, Weder W, Stahel RA, Felley-Bosco E. 2015. Prevalence of BRCA-1 563 
associatedprotein1germlinemutation in sporadic malignant pleural mesothelioma cases. Lung Cancer 87(1):77-9. 564 
doi:10.1016/j.lungcan.2014.10.017.  565 
[43] Sneddon S, Leon JS, Dick IM, Cadby G, Olsen N, Brims F, Allcock RJ, Moses EK, Melton PE, de Klerk N, Musk 566 
AW, Robinson BW, Creaney J. Absence of germline mutations in BAP1 in sporadic cases of malignant 567 
mesothelioma.Gene. 2015 May25;563(1):103-5. doi: 10.1016/j.gene.2015.03.031.  568 
[44] Jovanovic P, Mihajlovic M, Djordjevic-Jocic J, Vlajkovic S, Cekic S, Stefanovic V. 2013. Ocular melanoma: an 569 
overview of the current status. Int J Clin Exp Pathol 6(7):1230-44.  570 
[45] Read J, Wadt KAW, Hayward NK. 2015. Melanoma genetics. J Med Genet 0:1-14. doi: 10.1136/jmedgenet-2015-571 
103150. 572 
[46] Arzt L, Quehenberger F, Halbwedl I, Mairinger T, Popper HH. 2014. BAP1 protein is a progression factor in 573 
malignant pleural mesothelioma. Pathol Oncol Res 20(1):145-51. doi: 10.1007/s12253-013-9677-2. 574 
17 
 
[47]Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, Yang H, Carbone M. 2015. Mesothelioma 575 
patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 36(1):76-81. doi: 576 
10.1093/carcin/bgu227. 577 
[48] Yoshikawa Y, Sato A, Tsujimura T, Emi M, Morinaga T, Fukuoka K, Yamada S, Murakami A, Kondo N, 578 
Matsumoto S, Okumura Y, Tanaka F, Hasegawa S, Nakano T, Hashimoto-Tamaoki T. 2012. Frequent inactivation of 579 
the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci 103(5):868-74. doi: 10.1111/j.1349-580 
7006.2012.02223.x. 581 
[49] Pedace L, De Simone P, Castori M, Sperduti I, Silipo V, Eibenschutz L, De Bernardo C, Buccini P, Moscarella E, 582 
Panetta C, Ferrari A, Grammatico P, Catricalà C. 2011. Clinical features predicting identification of CDKN2A 583 
mutations in Italian patients with familial cutaneous melanoma.Cancer Epidemiol 35(6):e116-20. 584 
[50] Ghiorzo P, Villaggio B, Sementa AR, Hansson J, Platz A, Nicoló G, Spina B, Canepa M, Palmer JM, Hayward 585 
NK, Bianchi-Scarrà G. 2004. Expression and localization of mutant p16 proteins in melanocytic lesions from familial 586 
melanoma patients.Hum Pathol 35(1):25-33. 587 
[51] Lo Iacono M, Monica V, Righi L, Grosso F, Libener R, Vatrano S, Bironzo P, Novello S, Musmeci L, Volante 588 
M,Papotti M, Scagliotti GV. 2015. Targeted next-generation sequencing of cancer genes in advanced stage malignant 589 
pleural mesothelioma: a retrospective study. J Thorac Oncol 10(3):492-9. doi: 10.1097/JTO.0000000000000436. 590 
[52] Kollipara R, Cooley LD, Horii KA, Hetherington ML, LeBoit PE, Singh V, Zwick DL. 2014. Spitzoid Melanoma 591 
in a Child with Li-Fraumeni Syndrome Pediatr Dev Pathol 17(1):64-69. doi: 10.2350/13-09-1380-CR.1. 592 
[53] Curiel-Lewandrowski C, Speetzen LS, Cranmer L, Warneke JA, Loescher LJ. 2011. Multiple primary cutaneous 593 
melanomas in Li-Fraumeni syndrome. Arch Dermatol 147(2):248-50. doi: 10.1001/archdermatol.2010.428. 594 
[54] Ceelen WP, Van Dalen T, Van Bockstal M, Libbrecht L, Sijmons RH. 2011. Malignant peritoneal mesothelioma in 595 
a patient with Li-Fraumenisyndrome. J Clin Oncol. 29(17):e503-5. doi: 10.1200/JCO.2010.34.1933. 596 
[55] Bacin F, Kemeny JL, D'Hermies F, Rozan R, Decroix P, Dalens H, Kalifa C. 1993. Malignant melanoma of the 597 
choroid associated with neurofibromatosis. J Fr Ophtalmol 16(3):184-90. 598 
[56] Baser ME, Rai H, Wallace AJ, Evans DG. 2005. Neurofibromatosis 2 (NF2) and malignant mesothelioma in a man 599 
with a constitutional NF2 missense mutation. Fam Cancer. 4(4):321-2.  600 
[57] Shields JA, Shields CL, Lavrich J. 2002. Melanocytoma of optic disk in a patient with neurofibromatosis 2 Retina 601 
22(2):222-3.   602 
[58] Zauderer MG, Bott M, McMillan R, Sima CS, Rusch V, Krug LM, Ladanyi M. 2013. Clinical Characteristics of 603 
Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations. J ThoracOncol 8(11):1430-3. doi: 604 
10.1097/JTO.0b013e31829e7ef9. 605 
[59] Sekido Y. 2013. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis 34(7):1413-9. doi: 606 
10.1093/carcin/bgt166. 607 
[60] AIRTUM Working Group. 2013. Italian cancer figures, report 2013: Multiple tumours. Epidemiol Prev 37(4-5 608 
Suppl 1):1-152. 609 
[61] Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, Tan Y, Menges CW, Cai KQ, Litwin S, Peng H, 610 
Karar J, Rauscher FJ, Testa JR. 2014. Germline mutation of Bap1 accelerates development of asbestos-induced 611 
malignant mesothelioma. Cancer Res 74(16):4388-97. doi: 10.1158/0008-5472.CAN-14-1328. 612 
 613 
URL 614 
http://www.ncbi.nlm.nih.gov/SNP/ 615 
http://www.1000genomes.org/1000-genomes-browsers 616 
http:// evs.gs.washington.edu/EVS/ 617 
http://exac.broadistitute.org 618 
http://www.ncbi.nlm.nih.gov/ 619 
http://www.ensembl.org 620 
http://www.mutationtaster.org 621 
http://sift.jcvi.org/www/SIFT_enst_submit.html 622 
http://provean.jcvi.org/seq_submit.php 623 
http://genetics.bwh.harvard.edu/pph2/ 624 
http://mutationassessor.org/v1 625 
http://bg.upf.edu/fannsdb/ 626 
http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index 627 
http://www.umd.be/HSF3/ 628 
http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq_acc.html 629 
http://www.fruitfly.org/seq_tools/splice.html 630 
http://www.cbs.dtu.dk/services/NetGene2/ 631 
18 
 
http://genes.mit.edu/GENSCAN.html 632 
http://www.softberry.com/berry.phtml?topic=fgenesh&group=help&subgroup=gfind 633 
http://www.softberry.com/berry.phtml?topic=fsplice&group=help&subgroup=gfind 634 
 635 
 636 
 637 
 638 
 639 
 640 
Figure 1 - Families with germline mutations 641 
 642 
The probands for each family are denoted by a black arrow. A plus symbol indicates individuals 643 
who carry germline mutations, a minus symbol indicates wild type individuals. A grey arrow 644 
denotes the mutation in the electropherograms. PB (peripheral blood), CM (cutaneous melanoma), 645 
MM (mesothelioma), FFPE (formalin-fixed paraffin-embedded). 646 
 647 
A. Family ID5. A1. Pedigree: the proband (II-4) had multiple cancers, her brother (II-1) had basal 648 
cell carcinoma of the skin and her mother (I-2) had gastric cancer. A2. Electropherograms: BAP1 649 
germline mutation (c.1153C>T p.Arg385*) was carried in PB and in both tumors of the proband (II-650 
4 PB, II-4 CM, II-4 MM). The proband’s healthy daughter (III-2 PB) also carries the mutation. 651 
Other family members were not available. A3. IHC: II-4 CM: cutaneous melanoma cells showed 652 
the expression of specific Melanoma Antigen (Melan A); the same cells showed the loss of BAP1 653 
nuclear expression(thin arrow), while BAP1 nuclear staining was retained in normal cells of the 654 
surrounding skin (thick arrow) and infiltrating inflammatory cellsII-4 MM: epithelioid 655 
mesothelioma cells showed the expression of specific mesothelial antigen (Calretinin); the same 656 
cells showed the loss of BAP1 nuclear expression (thin arrows), while BAP1 nuclear staining was 657 
retained in the normal endothelial cells and infiltrating inflammatory cells (thick arrows). 658 
 659 
B. Family ID16. B1. Pedigree: the proband (IV-1) had two cutaneous amelanotic melanomas, her 660 
mother (III-5) had non-Hodgkin cutaneous lymphoma and her paternal uncle (III-2) had cutaneous 661 
melanoma. B2. Electropherograms: a BAP1 missense mutation (c.1700A>C p.Asp567Ala) was 662 
found in the proband (IV-1 PB), in a sister (IV-2 PB), in her mother (III-5 PB) and in her maternal 663 
aunt (III-6 PB). The mutation was heterozygous also in both cutaneous amelanotic melanomas of 664 
the proband (IV-1 CM_1, IV-1 CM_2). B3. Microsatellite marker (D3S3026): a decreased amount 665 
of paternal allele was shown in a specimen from the second melanoma developed by the proband 666 
(IV-1 T, grey arrow) as compared with genomic DNA. B4. IHC: BAP1 was normallyexpressed in 667 
the nucleus of both cutaneous amelanotic melanomas of the proband (IV-1 CM_1 and IV-1 CM_2). 668 
 669 
C. Family ID3. C1. Pedigree: the proband (III-3) had cutaneous melanoma, the proband’s mother 670 
(II-3) had cutaneous melanoma and mesothelioma. C2. Electropherograms: CDKN2A germline 671 
mutation (c.301G>T p.Gly101Trp) was detected in the proband (III-3 PB) and in the proband’s 672 
mother (II-3 FFPE non-tumor tissue, II-3 MM). Melanoma specimen of II-3 wasnotavailable. C3. 673 
IHC: epithelioid mesothelioma from the proband’s mother (II-3 MM) showed intranuclear 674 
positivity to anti p16 antibody in neoplastic cells (left panel). The intensity of nuclear expression 675 
was slightly lower in less differentiated tumor cells (right panel). 676 
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Table I – Concise clinical details and testing results of the 40 probands 690 
 691 
Family 
ID (sex) 
Proband’s tumors (age at diagnosis) Family history BAP1 CDKN2A 
CDK4 
(ex2) 
TERT 
(prom) 
MITF 
(p.Glu318Lys) 
POT1 
(ex10) 
Other 
genes 
Probands/families with both mesothelioma and melanoma 
1 (F) Cutaneous melanoma (33) 
Biphasic mesothelioma (mother) 
Breast cancer (maternal grandmother) 
wt wt wt wt wt wt  
2 (F) 
Nasopharynx carcinoma (24) 
Cutaneous melanoma (43) 
Rectal carcinoma (56) 
Mesothelioma (father) 
other tumors in relatives of the 
paternal family 
wt wt wt wt wt wt 
TP53 
wt 
3 (F) Cutaneous melanoma (42) 
Mesothelioma and cutaneous 
melanoma (mother) 
wt 
c.301G>T 
p.Gly101Trp 
wt nd wt nd - 
4 (F) 
Cutaneous melanoma (30) 
Breastcancer (58) 
Mesothelioma (father), breast cancer 
(mother), papillary renal cell 
carcinoma type 2 (brother) 
c.-247dupCCTTCGC 
CCCCGTCCCTCC 
wt wt wt wt nd - 
5 (F) 
Meningioma (37) 
Cutaneous melanoma (53) 
Epithelioid pleura lmesothelioma (53) 
Cutaneous melanoma (57) 
Gastric cancer (mother), basal cell 
carcinoma of the skin (brother) 
c.1153C>T 
p.Arg385* 
wt wt wt wt wt - 
6 (M) Epithelioid mesothelioma (65) Melanoma (brother) wt wt wt wt wt nd - 
Probands/families with melanoma (without mesothelioma) and features of inherited cancer predisposition 
7 (F) 
Bilateral uveal melanoma (25, 30) 
Breast cancer (in situ, 40) 
Acustic neurinoma (sister), bladder 
(mother), head/neck tumors in both 
maternal and paternal families 
wt wt wt wt wt wt 
BRCA1 
BRCA2 
wt 
8 (M) Iris-Uveal melanoma (31) Negative wt wt wt wt wt wt - 
9 (F) 
Uveal melanoma (67) 
Cutaneous melanoma (72) 
Cutaneous melanoma (daughter, 
niece) 
wt wt wt wt wt nd - 
10 (F) 
Choroidal melanoma (63) 
Bilateral breast cancer (60, 65) 
Breast cancer (sister, maternal cousin, 
paternal aunt), renal cancer (maternal 
aunt) 
wt wt wt wt wt wt 
TP53 
BRCA1 
BRCA2 
wt 
11 (F) Cutaneous melanoma (46) Ocular melanoma (uveal, father), wt wt wt wt wt wt - 
2 
 
colon cancer 
12 (F) 
Renal cell cancer (41) 
Two synchronous cutaneous 
melanomas (43) 
Negative wt wt wt wt wt wt - 
13 (M) Lentigo maligna melanoma (65) 
Cutaneous melanoma, renal cell 
cancer 
wt wt wt wt wt wt - 
14 (M) 
Lentigo melanoma (54) 
Two synchronous cutaneous primary 
melanomas (58) 
Cutaneous melanoma (mother), renal 
cell cancer + uterus cancer + breast 
cancer (sister), pancreatic carcinoma, 
liver cancer, prostate cancer 
wt wt wt wt wt wt - 
15 (F) 
Two cutaneous primary melanomas 
(34, 40) 
Cutaneous melanoma (paternal 
uncles), renal cell cancer (father), 
lung cancer (two paternal uncles) 
wt wt wt wt wt wt - 
16 (F) 
Two cutaneous amelanotic 
melanomas (24, 25) 
Cutaneous melanoma (paternal 
uncle), non-Hodgkin cutaneous 
lymphoma (low grade, CD20+, 
mother) 
c.1700A>C 
(p.Asp567Ala) 
c.-594dupCCCGT 
wt wt wt wt wt - 
17 (F) 
Two cutaneous primary melanomas 
(31, 33) 
Cutaneous melanoma (father) wt wt wt wt wt wt - 
18 (F) Two cutaneous melanomas (56, 57) Cutaneous melanoma (father) wt wt wt wt wt wt - 
19 (F) 
Two synchronous cutaneous primary 
melanomas (67) 
Facial basal cell carcinoma (69)  
Cutaneous melanoma (brother), breast 
cancer, CNS, prostate cancer 
wt wt wt wt wt wt - 
20 (M) Cutaneous melanoma (20) 
Cutaneous melanoma (mother), breast 
and colon cancer 
wt wt wt wt wt wt - 
21 (M) Cutaneous melanoma (24) 
Cutaneous melanoma (mother), 
prostate cancer, vulvar cancer 
wt wt wt wt wt wt - 
22 (F) Cutaneous melanoma (in situ, 27) 
Cutaneous melanoma (father), 
prostate cancer 
wt wt wt wt wt wt - 
23 (M) Cutaneous melanoma (32) Cutaneous melanoma (sister) wt wt wt wt wt wt - 
24 (F) Cutaneous melanoma (35) 
Cutaneous melanoma + thyroid 
cancer (father) 
wt wt wt wt wt wt - 
25 (F) Cutaneous melanoma (39) 
Cutaneous melanoma + colon cancer 
(brother) 
wt wt wt wt wt wt - 
3 
 
26 (M) Cutaneous melanoma (82) 
Cutaneous melanoma (brother), 
pancreatic cancer (sister) 
wt wt wt wt nd nd - 
27 (M) 
Testicular teratoma (27) 
Multinodular goiter 
Ten cutaneous primary melanomas 
(38 to 52) 
Breast cancer (mother) wt p.Thr77Ala§ wt wt wt wt - 
28 (M) 
Lipoma (27) 
Adrenal cortex adenoma (53) 
Three cutaneous primary melanomas 
(57, 58) 
Prostate cancer (father), liver cancer 
(paternal uncle and paternal 
grandfather) 
wt wt wt wt wt wt - 
29 (M) Cutaneous melanoma (61) 
Breast cancer (sister and two paternal 
aunts), lung cancer (paternal uncle) 
wt wt wt wt wt nd - 
Probands/families with mesothelioma (without melanoma) and features of inherited cancer predisposition 
30 (F) Epithelioid pleural mesothelioma (46) Mesothelioma (mother) wt wt wt wt wt nd - 
31 (M) Biphasic peritoneal mesothelioma(49) 
Mesothelioma (three sisters and 
brother) 
nd^,* wt wt nd* nd* nd* - 
32 (M) Biphasic pleural mesothelioma (53) 
Mesothelioma (paternal uncle and two 
cousins), leukemia (twin brother of 
the father) 
wt wt wt wt wt nd - 
33 (M) Epithelioid pleural mesothelioma (55) 
Mesothelioma (paternal 
grandmother), prostate cancer (father) 
wt wt wt wt wt nd - 
34 (M) Epithelioid pleural mesothelioma (68) Mesothelioma (sister and nephew) wt wt wt wt wt nd - 
35 (M) Epithelioid pleural mesothelioma (70) 
Mesothelioma (both parents), 
papillary thyroid carcinoma 
(daughter) 
wt wt wt wt wt nd - 
36 (M) Sarcomatoid mesothelioma (66) Mesothelioma (father and cousin) wt wt wt wt wt nd - 
37 (M) 
Mesothelioma 
Neuroblastoma  
Negative nd^,* nd* nd* nd* nd* nd* - 
38 (F) 
Epithelioid mesothelioma (28) 
Hodgkin linfoma (18) 
Negative wt wt wt wt wt nd - 
39 (M) 
Epithelioid mesothelioma  
Basalioma 
Negative nd^,* nd* nd* nd* nd* nd* - 
40 (F) Epithelioid mesothelioma (69) Lung cancer (uncertain diagnosis, wt nd nd nd nd nd - 
4 
 
mother) 
wt (wild type), nd (not done) 692 
^IHC: normal  nuclear expression; *Germline DNA not  available or very scanty 693 
 694 
§ This patient was reported by Pastorino et al. (2008) [1]. The authors considered this variant as possibly damaging, using a single prediction tool (Polyphen). We have integrated 695 
this in silico analysis using six prediction tools, i.e. Mut taster, SIFT, Provean, Mut assessor, Condel, and Phyre2. To assess a possible aberrant splicing we used Human Splicing 696 
Finder, MaxEnt, BDGP, NetGene2, GeneScan, FGENESH 2.6 and FSPLICE 1.0. Four out of seven disease-causing prediction tools reported the p.Thr77Ala variant as neutral.  697 
No data are reported for LOH, IHC and segregation analysis. Moreover, none of the 7 splice-site prediction tools has shown the creation of alternative splice sites for this variant. 698 
Thus, we concluded that the p.Thr77Ala variant should be considered as a VUS and the patient was considered eligible for mutation analysis in other genes. 699 
 700 
[1] Pastorino L, Bonelli L, Ghiorzo P, Queirolo P, Battistuzzi L, Balleari E, Nasti S, Gargiulo S, Gliori S, Savoia P, Abate Osella S, Bernengo MG, Bianchi Scarrà G. 2008. 701 
CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma. Pigment CellMelanomaRes 21(6):700-9. doi: 10.1111/j.1755-702 
148X.2008.00512.x.  703 
 704 
 705 
 706 
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Supplementary Figure 1- BAP1 germline duplications 
The proband is denoted by a black arrow. A plus symbol indicates individuals with germline 
variant. A grey arrow denotes the mutation in the electropherogram. PB (peripheral blood). 
 
A. Family ID16. Pedigree is reported in Figure 1B. A1. Electropherogram: a new germline 5bp 
duplication (c.-594dupCCCGT) in the BAP1 promoter region was found in the proband (IV-1 PB), 
in a sister (IV-2 PB), in her mother (III-5 PB) and in her maternal aunt (III-6 PB). This duplication 
is in cis with the p.Asp567Ala missense variant. 
 
B. Family ID4. B1. Pedigree: the proband (II-1) had cutaneous melanoma and breast cancer, the 
brother (II-2) had papillary renal cell carcinoma type 2, the father (I-1) died for mesothelioma and 
the mother (I-2) had breast cancer. B2. Electropherogram: a new germline 19bp duplication (c.-
247dupCCTTCGCCCCCGTCCCTCC) in the BAP1 promoter region was found in the proband (II-
1 PB). No specimens from relatives were available for segregation analysis. 
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Supplementary Figure 1  
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Supplementary Figure 2 - Predicted structure of BAP1 protein 
Predicted structure of BAP1 protein according to Protein Homology/analogY Recognition Engine v 
2.0 (Phyre2). The yellow arrows indicate the position of D567 (a) or the mutant A567 (b). 
The wild type negative charged D567 seems to localize at the interface with the ubiquitin carboxy-
terminal hydrolase domain (residues 1-240) depicted in dark to light blue with the catalytic sites 
Q85, C91, H169 and D184 shown in white. Known domains are indicated with different colours 
according to their position: HCFC1 binding motif in green (residues 363-366), the long alpha helix 
of the BRCA1 binding domain in orange (residues 629-659/669) and the Nuclear Localization 
Signal (NLS, residues 717-722) in red. 
The mutant hydrophobic A567 is predicted buried within the globular portion of the protein and the 
relevant domains of the BAP1 protein seem to assume a different position. 
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Supplementary Figure 2  
a) 
 
 
b) 
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Supplementary Table I – Probands clinical data 
 
Family ID (sex) 
Age at 
diagnosis 
Proband’s tumors Other clinical information 
Asbestos 
exposure  
Follow-up 
(years) 
Family history 
Cases/families with the association of cutaneous melanoma and mesothelioma 
1 (F) 33 
Cutaneous melanoma of the left leg  
(superficial spreading melanoma, 
0.46 mm Breslow thickness, Stage IA) 
No dysplastic nevi, 
10-50 melanocytic nevi, 
Fitzpatrick skin phototype II  
Not registered 
(mother) 
No relapse 
(5) 
Mesothelioma (mother), breast 
cancer (maternal grandmother) 
2 (F) 43 
Cutaneous melanoma of the abdomen 
(superficial spreading melanoma, 
0.20 mm Breslow thickness, Stage pT1) 
High grade naso pharynx 
carcinoma with lymph node 
metastasis (24) 
Rectal carcinoma (56) 
Not registered 
(father) 
Exitus for 
metastatic 
rectal 
carcinoma 
(14) 
Mesothelioma (father) and other 
tumors in the paternal family 
3 (F)  41 
Cutaneous melanoma 
(superficial spreading melanoma, 1.00 mm 
Breslow thickness Stage IB) 
Previous excision of several 
dysplastic nevi 
Fitzpatrick skin phototype II 
Possible 
occupational 
exposure as 
cotton weaver 
for 5 years 
(mother) 
No relapse 
(10) 
Mesothelioma and cutaneous 
melanoma (mother)  
4 (F) 30 
Cutaneous melanoma of the left leg 
(superficial spreading melanoma, Breslow 
thickness not available) 
Breast cancer (58) 
Not registered 
(father) 
Subcutane
ous 
metastasis 
(35) 
Mesothelioma (father), breast cancer 
(mother), papillary renal cell 
carcinoma type 2 (brother) 
5 (F)  53  
Cutaneous melanoma of the ear (53) 
(superficial spreading melanoma, 1.1 cm 
Breslow thickness Stage pT2a), ephitelioid 
pleural mesothelioma (53), cutaneous 
melanoma of the scalp (57) 
Meningioma (37) 
No exposure to 
asbestos could 
be identified, 
but residential 
history was 
incomplete 
No relapse 
(5) 
Gastric cancer (mother), basal cell 
carcinoma of the skin (brother) 
6 (M)  65 Epithelioid mesothelioma - 
No interview 
available 
(3) 
Melanoma (brother), colon cancer 
(father) 
Cases/families with melanoma (without mesothelioma) and with familiarity for BAP1 associated tumors 
(i.e. early onset melanoma, either ocular or cutaneous, multiple primary tumors, positive family history, development of other tumors except mesothelioma) 
10 
 
Family ID (sex) 
Age at 
diagnosis 
Proband’s tumors Other clinical information 
Asbestos 
exposure  
Follow-up 
(years) 
Family history 
7 (F) 25 and 30 Bilateral ocular melanoma (uvea) 
In situ ductal breast tumor 
(40) 
- 
No relapse 
(23) 
Acustic neurinoma (sister), larynx 
tumor (father and two paternal 
relatives), bladder tumor (mother) 
8 (M)  31 and 33 Ocular melanoma (iris-uvea)  
No dysplastic nevi 
<10 melanocytic nevi 
Fitzpatrick skin phototype III 
- 
No relapse 
(5) 
Negative 
9 (F)  67 and 72 
Ocular melanoma (uvea) and cutaneous 
melanoma (1st Clark level) 
Thyroidectomy for goiter 
(58) 
Schwannoma of the auditory 
nerve - facial dx (71) 
- 
No relapse 
(1) 
Cutaneous melanoma (daughter and 
niece), lung cancer (father) 
10 (F) 63 Ocular melanoma (choroid) 
Bilateral breast cancer (60, 
65) 
- 
No relapse 
(7) 
Breast cancer (sister, maternal 
cousin, paternal aunt), renal cancer 
(maternal aunt) 
11 (F) 46 
Cutaneous melanoma of the abdomen 
(superficial spreading melanoma, 0.20 mm 
Breslow thickness, Stage IA) 
No dysplastic nevi, 
<10 melanocytic nevi 
- 
No relapse 
(4) 
Ocular melanoma (uveal, father), 
colon cancer 
12 (F) 43 
Two synchronous cutaneous melanomas of 
left and right leg (superficial spreading 
melanoma, 0.20 and 0.28mm Breslow 
thickness, Stage IA)  
No dysplastic nevi, 
<10 melanocytic nevi,  
Fitzpatrick skin phototype III 
Renal cell cancer, clear cells 
with focal areas of papillary 
architecture (41) 
- 
No relapse  
(4) 
Negative 
13 (M)  65 
Lentigo maligna melanoma of the right 
forearm (0.23mm Breslow thickness, Stage 
IA) 
No dysplastic nevi 
Fitzpatrick skin phototype II 
- 
No relapse 
(13) 
Cutaneous melanoma (daughter, 
nephew), renal cell carcinoma 
(brother) 
14 (M)  54 and 58 
Three cutaneous primary melanomas: 
lentigo melanoma of the left cheekbone 
(Stage 0); two synchronous cutaneous 
melanomas of the left shoulder and lumbar 
region (superficial spreading 
melanoma  0.65 mm Breslow thickness, 
Stage IA and 2.34 mm Breslow thickness, 
Stage IIIB) 
No dysplastic nevi, 
>50 melanocytic nevi,  
Fitzpatrick skin phototype I 
- 
Exitus for 
metastatic 
melanoma  
(5) 
Cutaneous melanoma (mother), renal 
cell carcinoma + uterus cancer + 
breast cancer (sister), pancreatic 
carcinoma, liver, prostate 
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Family ID (sex) 
Age at 
diagnosis 
Proband’s tumors Other clinical information 
Asbestos 
exposure  
Follow-up 
(years) 
Family history 
15 (F)  34 and 40 
Two cutaneous primary melanomas of the 
supraclavear left and left breast regions 
(superficial spreading melanomas, 0.64 and 
0.23 mm Breslow thickness, Stage IA) 
No dysplastic nevi, 
> 50 nevi melanocytic nevi, 
Fitzpatrick skin phototype III 
- 
No relapse 
(10) 
 
Cutaneous melanoma (paternal 
uncles), renal cell cancer (father), 
lung cancer (two paternal uncles) 
16 (F) 24 and 25 
Two cutaneous amelanotic melanomas of 
the left shoulder and of the right arm 
(nodular melanoma, 1.80 mm Breslow 
thickness, Stage IB and superficial 
spreading melanoma, 0.30 mm Breslow 
thickness, Stage IA) 
No dysplastic nevi, 
 >50 clinical atypical 
melanocytic nevi 
Fitzpatrick skin phototype II 
- 
No relapse 
(9) 
Cutaneous melanoma (paternal 
uncle), non-Hodgkin cutaneous 
lymphoma (low grade, CD20+, 
mother) 
17 (F) 31 and 33 
Two cutaneous primary melanomas 
(superficial spreading melanoma, Breslow 
thickness not available) 
- - 
Not 
available 
Cutaneous melanoma (father) 
18 (F)  56 and 57 
Two cutaneous melanomas (superficial 
spreading melanoma, Breslow thickness 
not available) 
- - 
Not 
available 
Cutaneous melanoma (father) 
19 (F)  67 
Two synchronous cutaneous melanomas of 
the right hip and of the right arm 
(superficial spreading melanoma, 0.20 mm 
Breslow thickness, Stage IA and melanoma 
in situ, Stage 0)  
No dysplastic nevi,  
<10 melanocytic nevi 
Fitzpatrick skin phototype II  
Facial basal cell carcinoma 
(69) 
- 
No relapse  
(4) 
Cutaneous melanoma (sister), breast 
cancer, CNS, prostate cancer 
20 (M)  20 
Cutaneous melanoma of left leg 
(superficial spreading melanoma, 0.52 mm 
Breslow thickness, Stage IA) 
No dysplastic nevi,  
<10 melanocytic nevi 
Fitzpatrick skin phototype II 
- 
No relapse 
(3) 
Cutaneous melanoma (mother), 
breast and colon cancer 
21 (M)  24 
Cutaneous melanoma of the abdomen 
(superficial spreading melanoma, 0.26 mm 
Breslow thickness, Stage IA) 
No dysplastic nevi,  
<10 melanocytic nevi,  
Fitzpatrick skin phototype II 
- 
No relapse  
(6) 
Cutaneous melanoma (mother), 
prostate cancer, vulvar cancer 
22 (F) 27 
Cutaneous in situ melanoma on the back 
(Stage 0) 
Dysplastic nevi,  
>50 melanocytic nevi,  
Fitzpatrick skin phototype II  
- 
No relapse  
(5) 
Cutaneous melanoma (father), 
prostate cancer 
23 (M)  32 
Cutaneous melanoma of the sternum 
(nodular melanoma, 2.10 mm Breslow 
thickness, Stage IIB) 
No dysplastic nevi, 
<10 melanocytic nevi, 
Fitzpatrick skin phototype II 
- 
No relapse 
(3) 
Cutaneous melanoma (sister) 
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Family ID (sex) 
Age at 
diagnosis 
Proband’s tumors Other clinical information 
Asbestos 
exposure  
Follow-up 
(years) 
Family history 
24 (F)  35 
Cutaneous melanoma of the right scapula  
(superficial spreading melanoma, 0.90 mm 
Breslow thickness, Stage IB) 
No dysplastic nevi, 
10-50 melanocytic nevi,  
Fitzpatrick skin phototype II 
- 
No relapse 
(3) 
Cutaneous melanoma + thyroid 
cancer (father) 
25 (F) 39 
Cutaneous melanoma (superficial 
spreading melanoma, Breslow thickness 
not available) 
- - 
Not 
available 
Cutaneous melanoma + colon cancer 
(brother) 
26 M  82 
Cutaneous melanoma of the back, (0.83 
mm Breslow thickness, 3rd Clark level)  
Fitzpatrick skin phototype 
III, chronic sun exposure 
- 
No relapse 
(1)  
Cutaneous melanoma (brother), 
pancreatic cancer (sister) 
27 (M) 38 to 52 Ten cutaneous primary melanomas  
Testicular teratoma (27) 
multinodular goiter  
- 
Not 
available 
Breast cancer (mother) 
28 (M)  57 and 58 Three cutaneous primary melanomas  
Lipoma (27) 
Adrenal cortex adenoma (53) 
- 
Not 
available 
Prostate cancer (father), liver cancer 
(paternal uncle and paternal 
grandfather) 
29 (M) 61 
Cutaneous melanoma of the back  
(4.6mm Breslow thickness, 5th Clark level) 
Fitzpatrick skin phototype 
III, sun exposure 
- 
No relapse 
(2) 
Breast cancer (sister and two paternal 
aunts), lung cancer (paternal uncle) 
Cases/families with mesothelioma (without melanoma) and with familiarity for BAP1 associated tumors  
(other mesothelioma cases among relatives, development of other tumors except melanoma) 
30 (F)  46 Epithelioid pleural mesothelioma - 
Household 
(low) 
No relapse 
(10) 
Biphasic mesothelioma (mother), 
lung cancer (father), bone cancer 
(maternal aunt), bowel cancer 
(maternal grandmother) 
31 (M) 49 Biphasic peritoneal mesothelioma - Household 
Exitus (7 
months) 
Mesothelioma (three sisters and 
brother) 
32 (M) 53 Biphasic pleural mesothelioma - 
Household 
(low) 
Exitus 
(5) 
Mesothelioma (paternal uncle and 
two cousins), leukemia (twin brother 
of the father) 
33 (M)  55 Epithelioid pleural mesothelioma - 
Possible 
occupational/ 
household 
(low) 
Not 
available 
Mesothelioma (paternal 
grandmother), prostate cancer 
(father) 
34 M 68 Epithelioid pleural mesothelioma - 
No interview 
available 
No relapse 
(1) 
Mesothelioma (sister and nephew) 
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Family ID (sex) 
Age at 
diagnosis 
Proband’s tumors Other clinical information 
Asbestos 
exposure  
Follow-up 
(years) 
Family history 
35 (M) 70 Epithelioid pleural mesothelioma - 
Household 
(low) 
No relapse 
(3) 
Mesothelioma (both parents), 
papillary thyroid carcinoma 
(daughter) 
36 (M) 66 Sarcomatoid mesothelioma - 
Possible 
occupational 
exposure as 
baker 1962-
1974 and 
residential 
exposure 1947-
1977 (in 
Stradella) 
No relapse 
(2) 
Mesothelioma (father and cousin), 
lung cancer (paternal uncle) 
37 (M)  
Not 
available 
Mesothelioma, neuroblastoma - 
Possible 
occupational 
exposure as 
pipe-fitter 2003-
2004, 
radiotherapy 
1985 (for 
neuroblastoma) 
Not 
available 
Negative 
38 (F)  28 and 18 
Epithelioid mesothelioma, Hodgkin 
linfoma  
- 
Para-
occupational 
exposure 1985-
1993 (father 
boiler and pipe-
fitter), 
radiotherapy 
2003 (for NHL) 
Exitus 
(5 months) 
Lung cancer (maternal cousin), 
leukemia (maternal cousin’s 
daughter) 
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Family ID (sex) 
Age at 
diagnosis 
Proband’s tumors Other clinical information 
Asbestos 
exposure  
Follow-up 
(years) 
Family history 
39 (M) 
Not 
available 
Epithelioid mesothelioma, basalioma - 
Possible 
occupational 
exposure as 
house-builder 
1944 and 1951-
1983 
Not 
available 
Negative 
 
40 (F) 69 
Epithelioid mesothelioma with metastasis 
on the scalp 
- 
Possible 
occupational 
exposure as 
cotton warper 
1950-1983 and 
household 
exposure 1982 
(removal of 
asbestos-cement 
roofing) 
No relapse 
(12) 
Lung cancer (uncertain diagnosis, 
mother) 
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Supplementary Table II – Primer sequences for the amplification of BAP1, CDKN2A, 
CDK4, MITF, TERT, POT1 genes. 
GENE PRIMERS SEQUENCES AMPLICON LENGTH (bp) 
 
  BAP1_prom1F 
  BAP1_prom2R 
GCTTTAGTCGTTGACACAGG  
  GGGAGAAAAGGCTCTTACCG  
1040 
  BAP1 
 
  BAP1_ex1-3F 
BAP1_ex1-3R 
  GAAGACGAGCCCAGAGG 
CGTAGGGTTCCTGGCACTGTC 
619 
  BAP1_ex4bisF 
BAP1_ex4bisR 
  TTCATAAGGAGACTGGGTGGA 
GACACAGAGAGTGGACTCAG 
597 
  BAP1_ex5F 
BAP1_ex5R 
  TGGGTATTTGGTAGGTGCTTG 
CTTTCCCCGCAACTGCATC 
486 
  BAP1_ex6-7F 
BAP1_ex6-7R 
  TCTGTGTTCCTTCCGATTCC 
GGTCGGGCAATATGGTGTAG 
562 
  BAP1_ex8F 
BAP1_ex8R 
  CGACCAGCTCCTGATTCC 
CCTGATCTTGCCAGATTCACC 
313 
  BAP1_ex9F 
BAP1_ex9R 
  CAGGTCTGCTGGTTCACTTCC 
CTATTCTCCCTCCCCACTCC 
531 
  BAP1_ex10F 
BAP1_ex10R 
  GGAAAGGTGGGACTTGGAG 
AGGGGCCTGTGGTAACAGC 
531 
  BAP1_ex11F 
BAP1_ex11R 
  GGCTGGGCTGTTCTTCTCTG 
GGAACCACATGGGAAAATTGC 
374 
  BAP1_ex12F 
BAP1_ex12R 
  CAGTGTAAGTGGGTGGCAGC 
CAAACTCCGCAGGTGCTCAAC 
425 
  BAP1_ex13F 
BAP1_ex13R 
  GGCTTAGCATGGCTAGTTCAAG 
GCAGGACACTTTGTGGTCAC 
715 
  BAP1_ex14F 
BAP1_ex14R 
  CTTGGACTGGCTCACTGGC 
GAAAGTCTTCTGGCACATGGC 
408 
  BAP1_ex15-16F 
BAP1_ex15-16R 
  GAAGACTTTCTGGGTTGGGTGG 
CCTGCGAAGAGGTAGAGACC 
591 
  BAP1_ex17F 
  BAP1_ex17R 
  CCTGAGGCTTGAGCAGACCTTG 
  GCTGTGCCCCAACTCCAGATG 
466 
CDKN2A 
 
p16_ex 1α F 
p16_ex 1α R 
GAAGAAAGAGGAGGGGCTG  
GCGCTACCTGATTCCAATTC 
340 
p14_ex 1β F 
p14_ex 1β R 
CGCTCAGGGAAGGCGGGTG 
ACCAAACAAAACAAGTGCCG 
407 
p16_ex 2F 
p16_ex 2R 
GGGGCTTGTGTGGGGGTCTG 
GTGCTGGAAAATGAATGCTCTG 
483 
p16_ex 3F 
p16_ex 3R 
CGGTAGGGACGGCAAGAGAG 
CCTGTAGGACCTTCGGTGACTGA 
179 
CDK4 
CDK4_ex 2F 
CDK4_ex 2R 
GCTGCAGGTCATACCATCCT 
ATCATCACACCCCACCTATAGG 
372 
MITF 
MITF_ex 9F 
MITF_ex 9R 
TGTGCTCTGCCTATTTCAGTG 
AAGAAAACCCCTTCAGGTAAGTT 
340 
TERT 
Prom F 
Prom R 
GTCCTGCCCCTTCACCTT 
AGCACCTCGCGGTAGTGG 
488 
POT1 
POT1_ex10F 
POT1_ex10R 
AGCTGATATTCAACCACACTCGT 
GCACAAAAGGCTAGGGAACTATC 
435 
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Supplementary Table III – In silico analyses of BAP1 exonic mutations 
BAP1 missense variants 
(exon) Genomic position on chr3 
[Ref] Case ID 
Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members 
1000G 
ExAC 
Mut 
taster 
SIFT Provean 
PolyPhen 
HumVar 
(HumDiv) 
Mutation 
assessor 
Condel Phyre2 LOH IHC Segregation analysis Splice site prediction Conclusion 
c.41T>A (p.Leu14His) 
(exon 2)  3:52443756A>T 
[23] NCI-1326 
RCC (40, 44, 46, 54, 57) in carriers / RCC in other family members 
- 
0,9999 
diseasecau
sing 
0,000 
damaging 
-6,04 
deleterious 
1,00 
probablyda
maging 
(1,00) 
2,48 
medium 
impact 
0,55568 
deleterious 
likely to 
affect 
function 
(highest 
score) 
clear LOH in 
proband’s tumors 
Loss of BAP1 
proteinexpressio
n 
Variant cosegregates 
with the RCC 
predisposition (LOD 
score 1.2) 
No alterations Disease causing 
c.277A>G (p.Thr93Ala) 
(exon 5) 3:52442072T>C 
[22] A 
Adenocarcinoma of Unknown Primitive Tumor, Breast Ca x3, RCC (37, 39, 40, 47, 47), Cervical Ca, CaSU in carriers /  
Esophagus Ca x2, Head and Neck Carcinoma, Lung Ca, Breast Ca in other family members 
- 
0,9999 
diseasecau
sing 
0,001 
damaging 
-4,56 
deleterious 
0,989 
probablyda
maging 
(0,999) 
3,875 
higt 
impact 
0,73011 
deleterious 
likely to 
affect 
function 
(highest 
score) 
RCC sample from the 
index case shows LOH 
for the 3pter-14.1 
chromosomal region 
(genomic position 0-
64Mb) as the unique 
acquired large 
genomic deletion in 
this tumor 
Loss of BAP1 
proteinexpression 
Variant segregates with 
RCC (Segregation 
analysis based on 
identity by descend -
IBD-) 
New cryptic acceptor 
site (Human Splicing 
Finder, MaxEnt) 
Disease causing 
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BAP1 missense variants 
(exon) Genomic position on chr3 
[Ref] Case ID 
Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members 
1000G 
ExAC 
Mut 
taster 
SIFT Provean 
PolyPhen 
HumVar 
(HumDiv) 
Mutation 
assessor 
Condel Phyre2 LOH IHC Segregation analysis Splice site prediction Conclusion 
c.299T>C (p.Leu100Pro) 
(exon 5) 3:52442050A>G 
[11] 
UM (45, 56), Cholangiocarcinoma (71), Urothelial Carcinoma (48) in carries / 
RCC, Brain Ca, Leukemia, Uterine Ca in other family members 
- 
0,9999 
diseasecausin
g 
0,000 
damagi
ng 
-6,62 
deleterious 
1,00 
probablyda
maging 
(1,00) 
3,77 
higt 
impact 
0,69994 
deleterious 
likely to 
affect 
function 
(highest 
score) 
LOH of 8 markers, 
consistent with 
monosomy 3 
nd 
Variant segregates with 
UM (mother-son) 
No alterations Disease causing 
c.539T>C (p.Leu180Pro) 
(exon 7) 3:52441231A>G 
[16] FUM124 
UM (60), CM (72), MM (71), BCC (56, 65, 68) in carriers /  
Breast Ca x2, BCC x6, SCC, Non-melanoma Skin Ca, CM x2, Prostate Ca, Uterine Ca, Liposarcoma, Melanoma (meningeal), Cervical Ca, CaSU x3, MM, GI 
TractCancer in otherfamilymembers 
- 
0,9999 
diseasecau
sing 
0,000 
damaging 
-6,90 
deleterious 
1,00 
probablyda
maging 
(1,00) 
3,725 
higt 
impact 
0,70362 
deleterious 
likely to 
affect 
function 
(highest 
score) 
nd nd 
Variant does not 
unconditionally track 
with the disease 
No alterations Disease causing 
c.1327A>T (p.Asn443Tyr) 
(exon 13)3:52437834T>A 
[14] 16  
UM in carrier / CaSU in otherfamilymembers 
- 
0,9997 
diseasecau
sing 
0,005 
damaging 
-0,89 
neutral 
0,855 
possiblyda
maging 
(0,994) 
0,55 
neutral 
0,46382 
neutral 
unlikely to 
affect 
function 
(highest 
score) 
nd nd no data No alterations  VUS 
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BAP1 missense variants 
(exon) Genomic position on chr3 
[Ref] Case ID 
Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members 
1000G 
ExAC 
Mut 
taster 
SIFT Provean 
PolyPhen 
HumVar 
(HumDiv) 
Mutation 
assessor 
Condel Phyre2 LOH IHC Segregation analysis Splice site prediction Conclusion 
c.1445C>T, 
p.Ser482Leu 
(exon 13)3:52437716G>A 
[14] 19 
UM in carrier / CM, Lung Ca x3 in otherfamilymembers 
- 
1 het 
60.463 
All 
0,9999 
diseasecau
sing 
0,104 
tolerated 
-0,71 
neutral 
0,057 
benign 
(0,760) 
0,895 
low 
impact 
0,472555 
neutral 
unlikely to 
affect 
function 
(highest 
score) 
nd nd no data 
New acceptor site 
(MaxEnt, NetGene2)  
VUS 
c.1708C>G 
p.Leu570Val 
(exon 13)3:52437453G>C 
[21] 
UM (18, 46, 62), CM (27, 27, 33), MM (47), Peritoneal MM (84), Lung Ca (46), Paraganglioma (42), Breast Ca (75), Malignant Fibrous Histiocytoma (45) in carriers / 
Prolactinoma in other family member 
- 
0,6937 
diseasecau
sing 
0,054 
tolerated 
-0,52 
neutral 
0,016 
benign 
(0,075) 
0,695 
neutral 
0,469014 
neutral 
unlikely to 
affect 
function 
(highest 
score) 
LOH in UM and PGL nd 
Variant segregates in 
this multi-cancer 
family 
Activation of a cryptic 
donor site 22bp before 
the end of the exon 
(Human Splicing 
Finder, MaxEnt, 
BDGP, NetGene2, 
GeneScan,FGENESH 
2.6, FSPLICE 1.0)  
Disease causing 
c.518A>G (p.Tyr173Cys) 
(exon 7)3:52441252T>C 
[17] 
UM (72), MM, adenocarcinoma in carriers / MM x2, RCC, ALL in otherfamilymembres 
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BAP1 missense variants 
(exon) Genomic position on chr3 
[Ref] Case ID 
Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members 
1000G 
ExAC 
Mut 
taster 
SIFT Provean 
PolyPhen 
HumVar 
(HumDiv) 
Mutation 
assessor 
Condel Phyre2 LOH IHC Segregation analysis Splice site prediction Conclusion 
- 
0,9999dis
easecausin
g 
0,000dam
aging 
-7,75                        
deleterious 
0,999proba
blydamagin
g(1,000) 
3,27mediu
m 
0,662034del
eterious 
likely to 
affect 
function 
(highest 
score) 
nd 
Loss of nuclear 
BAP1 labeling in 
adenocarcinoma 
but nuclear 
labeling for 
BAP1 was 
retained in the 
MM (No UM 
specimen 
available) 
no data 
Activation of an exonic 
cryptic donor site 
(Human Splicing 
Finder, MaxEnt)  
Disease causing 
c.233A>G(p.Asn78Ser) 
(exon 4) 52442512T>C 
[6] ABS2570  
Kidney Ca, MM in carriers / Gastic Ca x4 in otherfamilymembres 
- 
0,9999dis
easecausin
g 
0,06tolerat
ed 
-3,80                       
deleterious 
0,608possi
blydamagin
g(0,767) 
0,7  
neutral 
0,442072ne
utral 
unlikely to 
affect 
function 
(high 
score) 
nd nd no data 
Activation of an exonic 
cryptic donor site 
(Human Splicing 
Finder, MaxEnt, 
BDGP, NetGene2, 
GeneScan, FSPLICE); 
Activation of an exonic 
acceptor site, with one 
or more cryptic branch 
point(s) (Human 
Splicing Finder  
Disease causing 
c.1748C>T (p.Ser583Leu) 
(exon 14)3:52437296G>A 
[6] ABS3313  
MM (67), BCC in carrier / CM in otherfamilymember 
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BAP1 missense variants 
(exon) Genomic position on chr3 
[Ref] Case ID 
Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members 
1000G 
ExAC 
Mut 
taster 
SIFT Provean 
PolyPhen 
HumVar 
(HumDiv) 
Mutation 
assessor 
Condel Phyre2 LOH IHC Segregation analysis Splice site prediction Conclusion 
- 
1 het   
6503 
All 
0.9871dis
easecausin
g 
0,38tolerat
ed 
-0,84                               
neutral 
0,001benig
n (0,001) 
0,345 
neutral 
0,451540ne
utral 
unlikely to 
affect 
function 
(high 
score) 
nd nd no data 
New acceptor site 
(MaxEnt)  
VUS 
c.1147C>T (p.Arg383Cys) 
(exon 12)3:52438572G>A 
[6] ABS3023 
MM in carrier / Breast Ca in otherfamilymember 
1 het  
6502 
All5 
het 
(4.471e
-05) 
0,9999dis
easecausin
g 
0,03 
damaging 
-2,51  
deleterious 
0,990proba
blydamagin
g(1,000) 
1,845                      
low 
impact 
0,489999ne
utral 
unlikely to 
affect 
function 
(high 
score) 
nd nd no data No alterations  VUS 
c.1700A>C (p.Asp567Ala) 
(exon 13) 52437461T>G 
[this work] ID16 
CM (28, 28), Cutaneous lymphoma NH-B (57) in carriers / 
- 
0,9999 
diseasecau
sing 
0,003 
damaging 
-1,71 
neutral 
0,696 
possiblyda
maging 
(0.976) 
0,975 
low 
impact 
0,48069 
neutral 
unlikely to 
affect 
function 
(high 
score) 
Melanoma sample 
show a decreased 
amount of the paternal 
allele, suggesting the 
loss of the wild type 
allele 
Two different 
melanomas of the 
index case show 
the normal BAP1 
expression in the 
nucleus 
Variant does not 
unconditionally track 
with the disease 
No alterations VUS 
More frequent missense variants reported in ExAc 
(heterozygote, homozygote and total individuals of the population at higher frequency) 
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BAP1 missense variants 
(exon) Genomic position on chr3 
[Ref] Case ID 
Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members 
1000G 
ExAC 
Mut 
taster 
SIFT Provean 
PolyPhen 
HumVar 
(HumDiv) 
Mutation 
assessor 
Condel Phyre2 LOH IHC Segregation analysis Splice site prediction Conclusion 
c.121G>A (p.Gly41Ser) 
(exon 3) 3:52443571C>T 
nn 
78 het 
2.506 
Asn 
0,9999 
diseasecau
sing 
0,369 
tolerated 
-3,12 
deleterious 
0.078 
benign 
(0,078) 
0,049 
neutral 
0,458715 
neutral 
unlikely to 
affect 
function 
(high 
score) 
- - - 
New cryptic donor site 
(MaxEnt) 
VUS / Likely 
benign 
c.869A>G (p.Asn290Ser) 
(exon 10) 3:52439843T>C 
nn 
54 het 
5.772 
Lat 
0,9998 
poly- 
morphism 
1,000 
tolerated 
-0,57 
neutral 
0.000 
benign 
(0,000) 
neg score 
neutral 
0,332615 
neutral 
unlikely to 
affect 
function 
(highest 
score) 
- - - No alterations Likely benign 
c.1201T>G (p.Tyr401Asp) 
(exon 12)3:52438518A>C 
nn 
20 het 
60.059 
All 
0,9999 
diseasecau
sing 
0,537 
tolerated 
-2,12 
neutral 
0.186 
benign 
(0,437) 
0,095 
neutral 
0,491095 
neutral 
unlikely to 
affect 
function 
(highest 
score) 
- - - No alterations 
VUS / Likely 
benign 
c.1786A>G (p.Ser596Gly) 
(exon 14) 3:52437258T>C 
nn 
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BAP1 missense variants 
(exon) Genomic position on chr3 
[Ref] Case ID 
Tumors in patients with BAP1 variants (Age of diagnosis) and in untested family members 
1000G 
ExAC 
Mut 
taster 
SIFT Provean 
PolyPhen 
HumVar 
(HumDiv) 
Mutation 
assessor 
Condel Phyre2 LOH IHC Segregation analysis Splice site prediction Conclusion 
740 het 
30 hom 
5.201 
Afr 
0,9999 
poly-
morphism 
0,393 
tolerated 
-0,01 
neutral 
0.000 
benign 
(0,000) 
neg score 
neutral 
0,390318 
neutral 
unlikely to 
affect 
function 
(highest 
score) 
- - - No alterations Benign 
c.1838C>T (p.Thr613Met) 
(exon 14) 52437206G>A 
nn 
128 het 
1 hom 
5.202 
Afr 
0,9999 
poly- 
morphism 
0,063 
tolerated 
-0,34 
neutral 
0.001 
benign 
(0,001) 
0,000 
neutral 
0,426829 
neutral 
unlikely to 
affect 
function 
(highest 
score) 
- - - No alterations Benign 
 
This table was modified from Rai et al. 2016 [16] 
RCC renal cell carcinoma, CaSU, Cancer site unknown, UM uveal melanoma, MM malignant mesothelioma, CM cutaneous melanoma, BCC basal cell carcinoma, ALL Acute 
lymphocytic leukemia, LOH loss of heterozygosity, IHC immunohistochemistry, Nd not done, NN none, VUS variant of unknown significance. 
 
 
 
